PT  - JOURNAL ARTICLE
AU  - Silberstein, S.D.
AU  - Holland, S.
AU  - Freitag, F.
AU  - Dodick, D.W.
AU  - Argoff, C.
AU  - Ashman, E.
TI  - Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
AID  - 10.1212/WNL.0b013e3182535d20
DP  - 2012 Apr 24
TA  - Neurology
PG  - 1337--1345
VI  - 78
IP  - 17
4099  - http://n.neurology.org/content/78/17/1337.short
4100  - http://n.neurology.org/content/78/17/1337.full
SO  - Neurology2012 Apr 24; 78
AB  - Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? Methods: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. Results and Recommendations: The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A). AAN=American Academy of Neurology; AE=adverse event; CI=confidence interval; ER=extended-release; MAM=menstrually associated migraine; PMP=perimenstrual period; RCT=randomized controlled trial